Photo: Toxophilus / Wikimedia Commons, CC BY-SA 4.0, cropped
Novo Nordisk Raises Its Outlook a Third Time as Wegovy Pill Sales Hit $810 Million: Is the Turnaround Real?
- Guidance raised (third time): 2026 adjusted sales and operating profit growth of -2% to +2% at constant exchange rates, up from -6% to 0%.
- Wegovy pill: DKK 5.39 billion (~$810 million) in Q3, up 53% from Q2 and above the DKK 4.62 billion consensus.
- Injectable Wegovy: DKK 20.4 billion, down 2% at constant currency. Combined US Wegovy sales rose 21%.
- Q3 adjusted sales: DKK 79.2 billion, up 4% at constant currency; adjusted operating profit up 27% to DKK 31.7 billion.
- Shares rose about 3%–6% in Copenhagen, still down about 13% this year. CEO Mike Doustdar warned a turnaround can't be established on one strong quarter.
A better quarter for Novo
Novo Nordisk, the Danish maker of Ozempic and Wegovy, reported third-quarter results on Wednesday, November 4, and raised its full-year outlook for the third time this year.
| Metric | Q3 2026 |
|---|---|
| Adjusted sales | DKK 79.2 billion (+4% at CER) |
| Adjusted operating profit | DKK 31.7 billion (+27%) |
| Wegovy pill | DKK 5.39 billion (~$810 million), +53% q/q |
| Injectable Wegovy | DKK 20.4 billion (-2% at CER) |
CER = constant exchange rates. Sources: Novo Nordisk, CNBC, Investing.com.
Shares rose as much as about 6% in Copenhagen before paring gains to around 3%. They're still down about 13% for the year. Novo's results helped lift European stocks on a day already buoyed by the US midterms (our report).
The pill is working
The star was oral Wegovy, the pill version of Novo's obesity drug. Sales of DKK 5.39 billion beat the DKK 4.62 billion consensus and grew 53% from the second quarter.
Pills matter because many patients prefer them to weekly injections, and they are easier to manufacture and distribute at scale.
The guidance
Novo now expects 2026 adjusted sales growth and adjusted operating profit growth of -2% to +2% at constant exchange rates, up from -6% to 0%.
That still means a roughly flat year. Novo is coming off a tough stretch of price cuts, competition from Eli Lilly and a leadership change.
The worries
- Injectables are slipping. Injectable Wegovy fell 2%, with a steeper drop in the US.
- Pricing. Obesity drug prices are under pressure from US policy and competition. Read about US drug tariffs and Europe's pharma giants.
- Pipeline. Citi kept a neutral rating, citing pricing uncertainty and no clear successor to Wegovy.
- The CEO's own caution. Mike Doustdar said the recovery is gaining traction but that a turnaround can't be established on the basis of a single strong quarter.
What it means for investors
- The obesity market is now a two-horse race between Novo and Lilly, with pills the next battleground.
- Healthcare is defensive, but not risk-free. Novo has shown how fast a market leader can fall when competition and pricing turn. It's a reason to own healthcare through a diversified fund. See recession-proof investing.
- Currency: Novo reports in Danish kroner. A stronger krone (tied to the euro) raises its value for North American investors.
What to watch next
- Wegovy pill launches in new markets.
- Eli Lilly's oral obesity drug progress.
- February 2027: Novo's full-year results and 2027 guidance.
Frequently asked questions
What did Novo Nordisk report for Q3 2026?
Novo Nordisk reported adjusted sales of DKK 79.2 billion, up 4% at constant exchange rates, and adjusted operating profit up 27% to DKK 31.7 billion. Wegovy pill sales of DKK 5.39 billion beat forecasts.
How much did the Wegovy pill sell?
Oral Wegovy generated DKK 5.39 billion, about $810 million, in the third quarter of 2026, up 53% from the second quarter and above the consensus estimate of DKK 4.62 billion.
Did Novo Nordisk raise its guidance?
Yes, for the third time in 2026. It now expects adjusted sales growth and adjusted operating profit growth of -2% to +2% at constant exchange rates, up from -6% to 0%.
Why are injectable Wegovy sales falling?
Injectable Wegovy sales fell 2% at constant exchange rates, reflecting price pressure, competition from Eli Lilly's Zepbound and patients switching to the pill. Combined US Wegovy sales, including the pill, still rose 21%.
Is Novo Nordisk stock a buy?
RiskStock doesn't make stock recommendations. Novo shares are still down about 13% this year, and analysts such as Citi remain cautious about pricing and the pipeline. CEO Mike Doustdar himself warned that one strong quarter doesn't prove a turnaround.
Primary sources
- CNBC — Novo shares jump 6% as Wegovy pill sales impress, drugmaker hikes outlook
- Novo Nordisk — Investor relations: financial results
- Investing.com — Novo Nordisk Q3 2026 slides: sales recover, outlook raised on GLP-1 growth
- Analytics Insight — Novo Nordisk raises 2026 outlook: Wegovy pill sales hit USD 810 million
- Investing.com — European shares gain on Novo's results; markets weigh U.S. midterms
Data & disclaimer: This article is for educational purposes only and is not financial or investment advice. Figures reflect data available as of Nov 4, 2026, and conditions change — always confirm current pricing, rates and rules with the provider before you act. Written by Elizabeta Dimoska. See our editorial standards and disclosure.
Comments